Table 4.

Adjusted RRs of developing ER+, ER, PR+, and PR breast cancer in relation to hormone levels in postmenopausal women of the ORDET cohort

Total testosterone (median nmol/L)ER+
ER
PR+
PR
Cases/controlsRR* (95% CI)Cases/controlsRR* (95% CI)Cases/controlsRR* (95% CI)Cases/controlsRR* (95% CI)
    1 (0.56)28/2311.0010/2311.0022/2311.0015/2311.00
    2 (0.87)38/2001.58 (0.93-2.67)7/2000.83 (0.31-2.22)32/2001.72 (0.97-3.08)14/2001.06 (0.50-2.25)
    3 (1.25)61/1932.65 (1.62-4.32)13/1931.62 (0.69-3.80)42/1932.32 (1.33-4.06)30/1932.47 (1.29-4.75)
    P for trend<0.0010.2370.0030.004
    Continuous1.61 (1.30-2.00)1.18 (0.80-1.74)1.52 (1.20-1.92)1.50 (1.13-2.00)
    P heterogeneity§0.390.64
Free testosterone (median pmol/L)
    1 (0.80)34/2081.007/2081.0025/2081.0016/2081.00
    2 (1.67)36/2081.05 (0.63-1.75)10/2081.45 (0.54-3.89)28/2081.14 (0.64-2.03)18/2081.10 (0.55-2.23)
    3 (3.28)57/2081.64 (1.03-2.62)13/2081.89 (0.74-4.83)43/2081.71 (1.00-2.91)25/2081.56 (0.81-3.01)
    P for trend0.0230.1920.0360.156
    Continuous1.30 (1.06-1.59)1.24 (0.85-1.82)1.35 (1.08-1.70)1.20 (0.91-1.59)
    P heterogeneity§0.920.82
Estradiol (median pmol/L)
    1 (10.1)38/2081.0011/2081.0025/2081.0024/2081.00
    2 (19.3)41/2081.09 (0.67-1.77)9/2080.83 (0.33-2.04)35/2081.41 (0.81-2.46)13/2080.56 (0.28-1.13)
    3 (32.5)48/2081.26 (0.79-2.02)10/2080.92 (0.38-2.23)36/2081.46 (0.84-2.54)22/2080.92 (0.50-1.69)
    P for trend0.3210.8870.2140.893
    Continuous1.12 (0.91-1.38)0.92 (0.66-1.28)1.24 (0.96-1.60)0.91 (0.73-1.15)
    P heterogeneity§0.540.35
SHBG (median nmol/L)
    1 (54.9)41/2081.0011/2081.0029/2081.0022/2081.00
    2 (91.6)47/2091.10 (0.69-1.76)10/2090.86 (0.36-2.09)39/2091.28 (0.75-2.16)19/2090.84 (0.44-1.60)
    3 (141.0)39/2070.97 (0.60-1.57)9/2070.81 (0.33-2.00)28/2070.98 (0.56-1.72)18/2070.83 (0.43-1.60)
    P for trend0.8710.6550.8810.595
    Continuous0.89 (0.74-1.07)0.91 (0.63-1.30)0.86 (0.69-1.06)0.91 (0.70-1.19)
    P heterogeneity§0.740.74
  • * Adjusted for age, age at first birth, and family history of breast cancer.

  • P value for trend from model with the median of tertiles entered as continuous variables.

  • Log transformed.

  • § Wald test for heterogeneity.